1
|
Candia-Puma MA, Machaca-Luque LY, Roque-Pumahuanca BM, Galdino AS, Giunchetti RC, Coelho EAF, Chávez-Fumagalli MA. Accuracy of Diagnostic Tests for the Detection of Chagas Disease: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2022; 12:2752. [PMID: 36359595 PMCID: PMC9689806 DOI: 10.3390/diagnostics12112752] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 11/03/2022] [Accepted: 11/04/2022] [Indexed: 11/02/2023] Open
Abstract
The present systematic review and meta-analysis about the accuracy of diagnostic tests aim to describe the findings of literature over the last thirty years for the diagnosis of Chagas disease (CD). This work aimed to determine the accuracy of diagnostic techniques for CD in the disease's acute and chronic phases. The PubMed database was searched for studies published between 1990 and 2021 on CD diagnostics. Fifty-six published studies that met the criteria were analyzed and included in the meta-analysis, evaluating diagnostic accuracy through sensitivity and specificity. For Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescent Antibody Technique (IFAT), Hemagglutination Test (HmT), Polymerase Chain Reaction (PCR), and Real-Time Polymerase Chain Reaction (qPCR) diagnosis methods, the sensitivity had a median of 99.0%, 78.0%, 75.0%, 76.0%, and 94.0%, respectively; while specificity presented a median of 99.0%, 99.0%, 99.0%, 98.0%, and 98.0%, respectively. This meta-analysis showed that ELISA and qPCR techniques had a higher performance compared to other methods of diagnosing CD in the chronic and acute phases, respectively. It was concluded utilizing the Area Under the Curve restricted to the false positive rates (AUCFPR), that the ELISA diagnostic test presents the highest performance in diagnosing acute and chronic CD, compared to serological and molecular tests. Future studies focusing on new CD diagnostics approaches should be targeted.
Collapse
Affiliation(s)
- Mayron Antonio Candia-Puma
- Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa 04000, Peru
- Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa 04000, Peru
| | - Laura Yesenia Machaca-Luque
- Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa 04000, Peru
- Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa 04000, Peru
| | - Brychs Milagros Roque-Pumahuanca
- Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa 04000, Peru
- Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa 04000, Peru
| | - Alexsandro Sobreira Galdino
- Laboratório de Biotecnologia de Microrganismos, Universidade Federal São João Del-Rei, Divinópolis 35501-296, MG, Brazil
| | - Rodolfo Cordeiro Giunchetti
- Laboratório de Biologia das Interações Celulares, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
- Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais, INCT-DT, Salvador 40015-970, BA, Brazil
| | - Eduardo Antonio Ferraz Coelho
- Programa de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
- Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
| | - Miguel Angel Chávez-Fumagalli
- Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa 04000, Peru
| |
Collapse
|
2
|
Orduña-Mayares D, Hernández-Camacho N, Escobedo-Ortegón FJ, Canché-Pool EB, Sosa-Gallegos SL, SalvadorZamora-Ledesma, ElenaVillagrán-Herrera M, Jones RW, Camacho-Macías B. Trypanosoma cruzi and Leishmania spp. in rodents in a peri-urban area of Central Mexico. Vet Parasitol Reg Stud Reports 2022; 35:100779. [PMID: 36184108 DOI: 10.1016/j.vprsr.2022.100779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 07/08/2022] [Accepted: 08/26/2022] [Indexed: 06/16/2023]
Abstract
Rodents are one of the most relevant groups of mammals involved in the process of zoonotic disease transmission. Their ability to adapt to anthropized environments allows them to come into contact with humans with often negative consequences for the latter. The present study designed to detect the presence of Trypanosoma cruzi and Leishmania spp. in rodents living in the peri-urban area of Queretaro in central Mexico. This research was carried out during two seasons of collection of wild and domestic rodents, in three localities within the peri-urban area of the state of Queretaro. These collections were carried out during the dry season of February-May 2017 and in the rainy season of August-November 2017. Samples were obtained from the tail tip, from which DNA was purified using the DNeasy Blood & Tissue Kit. End-point PCR was used for the identification of Trypanosoma cruzi and Leishmania spp. A total of 82 rodents were caught, represented in three families, six genera and seven species, of which 29 (35.3%) were positive for Trypanosoma cruzi; 13 (15.8%) for Leishmania spp.; and 12 individuals presented co-infection with both parasites (14.6%). This study confirmed the presence of Trypanosoma cruzi and Leishmania spp. in synanthropic rodents in the peri-urban area of Queretaro, where Chagas and Leishmaniosis diseases are not considered endemic. It is necessary to continue researching for the presence of vectors, as well as for the detection of diseases caused by parasites in humans and thus be able to confirm the transmission cycle of Trypanosoma cruzi and Leishmania spp. in this central Mexican city.
Collapse
Affiliation(s)
- Diana Orduña-Mayares
- Faculty of Natural Sciences, Academic Body of Ecology and Faunal Diversity, The Universidad Autónoma de Querétaro, Mexico
| | - Norma Hernández-Camacho
- Faculty of Natural Sciences, Academic Body of Ecology and Faunal Diversity, The Universidad Autónoma de Querétaro, Mexico.
| | - Francisco Javier Escobedo-Ortegón
- Hideyo Noguchi Regional Research Centre, Academic Body of Ecological and Geographical Surveillance of Endemic, Emerging and Re-emerging Zoonoses in the Yucatan Peninsula, Universidad Autónoma de Yucatán, Mexico
| | - Elsy Beatriz Canché-Pool
- Hideyo Noguchi Regional Research Centre, Academic Body of Ecological and Geographical Surveillance of Endemic, Emerging and Re-emerging Zoonoses in the Yucatan Peninsula, Universidad Autónoma de Yucatán, Mexico
| | - Susana Lucía Sosa-Gallegos
- Faculty of Natural Sciences, Academic Body of Integral Animal Improvement, The Universidad Autónoma de Querétaro, Mexico
| | - SalvadorZamora-Ledesma
- Faculty of Natural Sciences, Academic Body of Ecology and Faunal Diversity, The Universidad Autónoma de Querétaro, Mexico
| | | | - Robert W Jones
- Faculty of Natural Sciences, Academic Body of Ecology and Faunal Diversity, The Universidad Autónoma de Querétaro, Mexico
| | - Brenda Camacho-Macías
- Faculty of Natural Sciences, Academic Body of Ecology and Faunal Diversity, The Universidad Autónoma de Querétaro, Mexico
| |
Collapse
|
3
|
Martín-Escolano R, Cebrián R, Maqueda M, Romero D, Rosales MJ, Sánchez-Moreno M, Marín C. Assessing the effectiveness of AS-48 in experimental mice models of Chagas' disease. J Antimicrob Chemother 2021; 75:1537-1545. [PMID: 32129856 DOI: 10.1093/jac/dkaa030] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 01/14/2020] [Accepted: 01/15/2020] [Indexed: 12/14/2022] Open
Abstract
OBJECTIVES We report the in vivo trypanocidal activity of the bacteriocin AS-48 (lacking toxicity), which is produced by Enterococcus faecalis, against the flagellated protozoan Trypanosoma cruzi, the aetiological agent of Chagas' disease. METHODS We determined the in vivo activity of AS-48 against the T. cruzi Arequipa strain in BALB/c mice (in both acute and chronic phases of Chagas' disease). We evaluated the parasitaemia, the reactivation of parasitaemia after immunosuppression and the nested parasites in the chronic phase by PCR in target tissues. RESULTS AS-48 reduced the parasitaemia profile in acute infection and showed a noteworthy reduction in the parasitic load in chronic infection after immunosuppression according to the results obtained by PCR (double-checking to demonstrate cure). CONCLUSIONS AS-48 is a promising alternative that provides a step forward in the development of a new therapy against Chagas' disease.
Collapse
Affiliation(s)
- Rubén Martín-Escolano
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain
| | - Rubén Cebrián
- Department of Microbiology, Faculty of Sciences, Avda. Fuentenueva s/n, University of Granada, 18071 Granada, Spain
| | - Mercedes Maqueda
- Department of Microbiology, Faculty of Sciences, Avda. Fuentenueva s/n, University of Granada, 18071 Granada, Spain
| | - Desirée Romero
- Department of Statistics and Operations Research, Faculty of Sciences, Avda. Fuentenueva s/n, University of Granada, 18071 Granada, Spain
| | - Maria José Rosales
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain
| | - Manuel Sánchez-Moreno
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain
| | - Clotilde Marín
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain
| |
Collapse
|
4
|
Martín-Escolano R, Etxebeste-Mitxeltorena M, Martín-Escolano J, Plano D, Rosales MJ, Espuelas S, Moreno E, Sánchez-Moreno M, Sanmartín C, Marín C. Selenium Derivatives as Promising Therapy for Chagas Disease: In Vitro and In Vivo Studies. ACS Infect Dis 2021; 7:1727-1738. [PMID: 33871252 PMCID: PMC8480776 DOI: 10.1021/acsinfecdis.1c00048] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Chagas disease is a tropical infection caused by the protozoan parasite Trypanosoma cruzi and a global public health concern. It is a paradigmatic example of a chronic disease without an effective treatment. Current treatments targeting T. cruzi are limited to two obsolete nitroheterocyclic drugs, benznidazole and nifurtimox, which lead to serious drawbacks. Hence, new, more effective, safer, and affordable drugs are urgently needed. Selenium and their derivatives have emerged as an interesting strategy for the treatment of different prozotoan diseases, such as African trypanosomiasis, leishmaniasis, and malaria. In the case of Chagas disease, diverse selenium scaffolds have been reported with antichagasic activity in vitro and in vivo. On the basis of these premises, we describe the in vitro and in vivo trypanocidal activity of 41 selenocompounds against the three morphological forms of different T. cruzi strains. For the most active selenocompounds, their effect on the metabolic and mitochondrial levels and superoxide dismutase enzyme inhibition capacity were measured in order to determine the possible mechanism of action. Derivative 26, with a selenocyanate motif, fulfills the most stringent in vitro requirements for potential antichagasic agents and exhibits a better profile than benznidazole in vivo. This finding provides a step forward for the development of a new antichagasic agent.
Collapse
Affiliation(s)
- Rubén Martín-Escolano
- Laboratory of Molecular & Evolutionary Parasitology, RAPID group, School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Mikel Etxebeste-Mitxeltorena
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Salud Tropical, Universidad de Navarra (ISTUN), Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Irunlarrea, 1, E-31008 Pamplona, Spain
| | - Javier Martín-Escolano
- Servicio de Microbiologia Clinica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
- Instituto de Investigación, Sanitaria Gregorio Marañón (IiSGM), 28009 Madrid, Spain
| | - Daniel Plano
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Salud Tropical, Universidad de Navarra (ISTUN), Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Irunlarrea, 1, E-31008 Pamplona, Spain
| | - María J. Rosales
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs. Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| | - Socorro Espuelas
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Salud Tropical, Universidad de Navarra (ISTUN), Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Irunlarrea, 1, E-31008 Pamplona, Spain
| | - Esther Moreno
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Salud Tropical, Universidad de Navarra (ISTUN), Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Irunlarrea, 1, E-31008 Pamplona, Spain
| | - Manuel Sánchez-Moreno
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs. Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| | - Carmen Sanmartín
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Salud Tropical, Universidad de Navarra (ISTUN), Irunlarrea, 1, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Irunlarrea, 1, E-31008 Pamplona, Spain
| | - Clotilde Marín
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs. Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| |
Collapse
|
5
|
Martín-Escolano R, Molina-Carreño D, Plano D, Espuelas S, Rosales MJ, Moreno E, Aydillo C, Sanmartín C, Sánchez-Moreno M, Marín C. Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting Trypanosoma cruzi Mitochondrion. Pharmaceuticals (Basel) 2021; 14:ph14050419. [PMID: 34062791 PMCID: PMC8147293 DOI: 10.3390/ph14050419] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 04/23/2021] [Accepted: 04/26/2021] [Indexed: 12/12/2022] Open
Abstract
Chagas disease is usually caused by tropical infection with the insect-transmitted protozoan Trypanosoma cruzi. Currently, Chagas disease is a major public health concern worldwide due to globalization, and there are no treatments neither vaccines because of the long-term nature of the disease and its complex pathology. Current treatments are limited to two obsolete drugs, benznidazole and nifurtimox, which lead to serious drawbacks. Taking into account the urgent need for strict research efforts to find new therapies, here, we describe the in vitro and in vivo trypanocidal activity of a library of selected forty-eight selenocyanate and diselenide derivatives that exhibited leishmanicidal properties. The inclusion of selenium, an essential trace element, was due to the well-known extensive pharmacological activities for selenium compounds including parasitic diseases as T. cruzi. Here we present compound 8 as a potential compound that exhibits a better profile than benznidazole both in vitro and in vivo. It shows a fast-acting behaviour that could be attributed to its mode of action: it acts in a mitochondrion-dependent manner, causing cell death by bioenergetic collapse. This finding provides a step forward for the development of a new antichagasic agent.
Collapse
Affiliation(s)
- Rubén Martín-Escolano
- Laboratory of Molecular & Evolutionary Parasitology, RAPID Group, School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK
- Correspondence: (R.M.-E.); (C.M.)
| | - Daniel Molina-Carreño
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain; (D.M.-C.); (M.J.R.); (M.S.-M.)
| | - Daniel Plano
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, E-31008 Pamplona, Spain; (D.P.); (S.E.); (E.M.); (C.A.); (C.S.)
- Instituto de Salud Tropical, Universidad de Navarra, ISTUN, Irunlarrea, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA) Irunlarrea, E-31008 Pamplona, Spain
| | - Socorro Espuelas
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, E-31008 Pamplona, Spain; (D.P.); (S.E.); (E.M.); (C.A.); (C.S.)
- Instituto de Salud Tropical, Universidad de Navarra, ISTUN, Irunlarrea, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA) Irunlarrea, E-31008 Pamplona, Spain
| | - María J. Rosales
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain; (D.M.-C.); (M.J.R.); (M.S.-M.)
| | - Esther Moreno
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, E-31008 Pamplona, Spain; (D.P.); (S.E.); (E.M.); (C.A.); (C.S.)
- Instituto de Salud Tropical, Universidad de Navarra, ISTUN, Irunlarrea, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA) Irunlarrea, E-31008 Pamplona, Spain
| | - Carlos Aydillo
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, E-31008 Pamplona, Spain; (D.P.); (S.E.); (E.M.); (C.A.); (C.S.)
- Instituto de Salud Tropical, Universidad de Navarra, ISTUN, Irunlarrea, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA) Irunlarrea, E-31008 Pamplona, Spain
| | - Carmen Sanmartín
- Facultad de Farmacia y Nutrición, Departamento de Tecnología y Química Farmacéuticas, Universidad de Navarra, Irunlarrea, E-31008 Pamplona, Spain; (D.P.); (S.E.); (E.M.); (C.A.); (C.S.)
- Instituto de Salud Tropical, Universidad de Navarra, ISTUN, Irunlarrea, E-31008 Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA) Irunlarrea, E-31008 Pamplona, Spain
| | - Manuel Sánchez-Moreno
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain; (D.M.-C.); (M.J.R.); (M.S.-M.)
| | - Clotilde Marín
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain; (D.M.-C.); (M.J.R.); (M.S.-M.)
- Correspondence: (R.M.-E.); (C.M.)
| |
Collapse
|
6
|
Martín-Escolano R, Guardia JJ, Martín-Escolano J, Cirauqui N, Fernández A, Rosales MJ, Chahboun R, Sánchez-Moreno M, Alvarez-Manzaneda E, Marín C. In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis. JOURNAL OF NATURAL PRODUCTS 2020; 83:3571-3583. [PMID: 33253573 DOI: 10.1021/acs.jnatprod.0c00651] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The life-long and life-threatening Chagas disease is one of the most neglected tropical diseases caused by the protozoan parasite Trypanosoma cruzi. It is a major public health problem in Latin America, as six to seven million people are infected, being the principal cause of mortality in many endemic regions. Moreover, Chagas disease has become widespread due to migrant populations. Additionally, there are no vaccines nor effective treatments to fight the disease because of its long-term nature and complex pathology. Therefore, these facts emphasize how crucial the international effort for the development of new treatments against Chagas disease is. Here, we present the in vitro and in vivo trypanocidal activity of some oxygenated abietane diterpenoids and related compounds. The 1,4-benzoquinone 15, not yet reported, was identified as a fast-acting trypanocidal drug with efficacy against different strains in vitro and higher activity and lower toxicity than benznidazole in both phases of murine Chagas disease. The mode of action was also evaluated, suggesting that quinone 15 kills T. cruzi by inducing mitochondrion-dependent necrosis through a bioenergetics collapse caused by a mitochondrial membrane depolarization and iron-containing superoxide dismutase inhibition. Therefore, the abietane 1,4-benzoquinone 15 can be considered as a new candidate molecule for the development of an appropriate and commercially accessible anti-Chagas drug.
Collapse
Affiliation(s)
- Rubén Martín-Escolano
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| | - Juan J Guardia
- Departamento de Química Orgánica, Facultad de Ciencias, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain
| | - Javier Martín-Escolano
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| | - Nuria Cirauqui
- Molecular Microbiology and Structural Biochemistry, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, 69367 Lyon Cedex 07, France
| | - Antonio Fernández
- Departamento de Química Orgánica, Facultad de Ciencias, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain
| | - Maria J Rosales
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| | - Rachid Chahboun
- Departamento de Química Orgánica, Facultad de Ciencias, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain
| | - Manuel Sánchez-Moreno
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| | - Enrique Alvarez-Manzaneda
- Departamento de Química Orgánica, Facultad de Ciencias, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain
| | - Clotilde Marín
- Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
| |
Collapse
|
7
|
Paucar R, Martín-Escolano R, Moreno-Viguri E, Azqueta A, Cirauqui N, Marín C, Sánchez-Moreno M, Pérez-Silanes S. Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation. Bioorg Med Chem 2019; 27:3902-3917. [DOI: 10.1016/j.bmc.2019.07.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 07/10/2019] [Accepted: 07/17/2019] [Indexed: 12/17/2022]
|
8
|
Arnal A, Waleckx E, Rico-Chávez O, Herrera C, Dumonteil E. Estimating the current burden of Chagas disease in Mexico: A systematic review and meta-analysis of epidemiological surveys from 2006 to 2017. PLoS Negl Trop Dis 2019; 13:e0006859. [PMID: 30964871 PMCID: PMC6474657 DOI: 10.1371/journal.pntd.0006859] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 04/19/2019] [Accepted: 03/15/2019] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND In Mexico, estimates of Chagas disease prevalence and burden vary widely. Updating surveillance data is therefore an important priority to ensure that Chagas disease does not remain a barrier to the development of Mexico's most vulnerable populations. METHODOLOGY/PRINCIPAL FINDINGS The aim of this systematic review and meta-analysis was to analyze the literature on epidemiological surveys to estimate Chagas disease prevalence and burden in Mexico, during the period 2006 to 2017. A total of 2,764 articles were screened and 36 were retained for the final analysis. Epidemiological surveys have been performed in most of Mexico, but with variable study scale and geographic coverage. Based on studies reporting confirmed cases (i.e. using at least 2 serological tests), and taking into account the differences in sample sizes, the national estimated seroprevalence of Trypanosoma cruzi infection was 3.38% [95%CI 2.59-4.16], suggesting that there are 4.06 million cases in Mexico. Studies focused on pregnant women, which may transmit the parasite to their newborn during pregnancy, reported an estimated seroprevalence of 2.21% [95%CI 1.46-2.96], suggesting that there are 50,675 births from T. cruzi infected pregnant women per year, and 3,193 cases of congenitally infected newborns per year. Children under 18 years had an estimated seropositivity rate of 1.51% [95%CI 0.77-2.25], which indicate ongoing transmission. Cases of T. cruzi infection in blood donors have also been reported in most states, with a national estimated seroprevalence of 0.55% [95%CI 0.43-0.66]. CONCLUSIONS/SIGNIFICANCE Our analysis suggests a disease burden for T. cruzi infection higher than previously recognized, highlighting the urgency of establishing Chagas disease surveillance and control as a key national public health priority in Mexico, to ensure that it does not remain a major barrier to the economic and social development of the country's most vulnerable populations.
Collapse
Affiliation(s)
- Audrey Arnal
- Departamento de Ecología de la Biodiversidad, Instituto de Ecología, Universidad Nacional Autónoma de México, Ciudad de México, México
- Centro de Investigaciones Regionales Dr Hideyo Noguchi, Universidad Autónoma de Yucatán, calle 96 s/n x av. Jacinto Canek y calle 47, Col. Paseo de las Fuentes, CP 97225, Mérida, Yucatán, México
| | - Etienne Waleckx
- Centro de Investigaciones Regionales Dr Hideyo Noguchi, Universidad Autónoma de Yucatán, calle 96 s/n x av. Jacinto Canek y calle 47, Col. Paseo de las Fuentes, CP 97225, Mérida, Yucatán, México
- Institut de Recherche pour le Développement, UMR INTERTRYP IRD, CIRAD, Université de Montpellier, Montpellier, France
| | - Oscar Rico-Chávez
- Departamento de Etología, Fauna Silvestre y Animales de Laboratorio, Facultad de Medicina Veterinaria Zootecnia, Universidad Nacional Autónoma de México, 04510 Ciudad de México, México
| | - Claudia Herrera
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, and Vector-Borne and Infectious Disease Research Center, Tulane University, 1440 Canal St., New Orleans, LA 70112, United States of America
| | - Eric Dumonteil
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, and Vector-Borne and Infectious Disease Research Center, Tulane University, 1440 Canal St., New Orleans, LA 70112, United States of America
| |
Collapse
|
9
|
Paucar R, Martín-Escolano R, Moreno-Viguri E, Cirauqui N, Rodrigues CR, Marín C, Sánchez-Moreno M, Pérez-Silanes S, Ravera M, Gabano E. A step towards development of promising trypanocidal agents: Synthesis, characterization and in vitro biological evaluation of ferrocenyl Mannich base-type derivatives. Eur J Med Chem 2019; 163:569-582. [DOI: 10.1016/j.ejmech.2018.12.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 11/29/2018] [Accepted: 12/02/2018] [Indexed: 02/06/2023]
|
10
|
Moreno-Viguri E, Jiménez-Montes C, Martín-Escolano R, Santivañez-Veliz M, Martin-Montes A, Azqueta A, Jimenez-Lopez M, Zamora Ledesma S, Cirauqui N, López de Ceráin A, Marín C, Sánchez-Moreno M, Pérez-Silanes S. In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives. J Med Chem 2016; 59:10929-10945. [DOI: 10.1021/acs.jmedchem.6b00784] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Elsa Moreno-Viguri
- Department
of Organic and Pharmaceutical Chemistry, Institute of Tropical Health, Universidad de Navarra, Pamplona 31008, Spain
| | - Carmen Jiménez-Montes
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Rubén Martín-Escolano
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Mery Santivañez-Veliz
- Department
of Organic and Pharmaceutical Chemistry, Institute of Tropical Health, Universidad de Navarra, Pamplona 31008, Spain
| | - Alvaro Martin-Montes
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Amaya Azqueta
- Department
of Pharmacology and Toxicology, Universidad de Navarra, Pamplona 31008, Spain
- IdiSNA, Navarra
Institute for Health Research, Recinto de Complejo Hospitalario de
Navarra, Pamplona 31008, Spain
| | - Marina Jimenez-Lopez
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Salvador Zamora Ledesma
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Nuria Cirauqui
- Department
of Pharmaceutical Sciences, Federal University of Rio de Janeiro, Rio de
Janeiro 21949-900, Brazil
| | - Adela López de Ceráin
- Department
of Pharmacology and Toxicology, Universidad de Navarra, Pamplona 31008, Spain
- IdiSNA, Navarra
Institute for Health Research, Recinto de Complejo Hospitalario de
Navarra, Pamplona 31008, Spain
| | - Clotilde Marín
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Manuel Sánchez-Moreno
- Departamento
de Parasitología, Instituto de Investigación Biosanitaria
(ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada 18014, Spain
| | - Silvia Pérez-Silanes
- Department
of Organic and Pharmaceutical Chemistry, Institute of Tropical Health, Universidad de Navarra, Pamplona 31008, Spain
| |
Collapse
|
11
|
Diagnosis of Congenital Chagas Disease Using an Iron Superoxide Dismutase Excreted as Antigen, in Mothers and Their Children During the First Year of Life. Pediatr Infect Dis J 2016; 35:739-43. [PMID: 27088584 DOI: 10.1097/inf.0000000000001174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Chagas disease caused by Trypanosoma cruzi is endemic in Latin America. Human infection is mainly spread by Triatominae insects. Other forms of transmission are congenital, blood transfusion and organ transplantation. METHODS Anti-T. cruzi antibodies were determined by enzyme-linked immunosorbent assay (ELISA) and Western blot (WB) in 155 serum samples from mothers and their babies. Indirect immunofluorescence (IFA) and a commercial test were used to validate efficacy of a specific ELISA-iron-excreted superoxide dismutase assay. Sera from babies were collected at 6 and 12 months, whereas maternal samples were obtained after delivery. Calostrum and umbilical cord samples were simultaneously obtained. RESULTS Anti-T. cruzi antibodies were detected in 8 (5.16%) mothers by ELISA-WB, in 7 (4.51%) using IFA and in 1 (0.64%) by a commercial kit. Nine (5.80%) 6-month-old children were positive by ELISA-WB and 7 (4.51%) by IFA; negative results were obtained when the commercial kit was used. At 12 month of age, 15 (9.67%) children were positive by ELISA-WB, 13 (8.38%) by IFA and 1 (0.64%) by the commercial test. Antibodies were detected in 4 mothers whose children were serologically negative. Four other mothers and their children were positive, but only one of them had detected antibodies in umbilical cord up to 12 months, thus assuming vertical transmission. CONCLUSIONS The use of iron-excreted superoxide dismutase as antigen in serologic tests for detection of T. cruzi yielded promising results as diagnostic procedure.
Collapse
|
12
|
In vitro and in vivo identification of tetradentated polyamine complexes as highly efficient metallodrugs against Trypanosoma cruzi. Exp Parasitol 2016; 164:20-30. [DOI: 10.1016/j.exppara.2016.02.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 02/04/2016] [Accepted: 02/05/2016] [Indexed: 12/20/2022]
|
13
|
An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase. INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE 2015; 5:110-6. [PMID: 26236582 PMCID: PMC4501536 DOI: 10.1016/j.ijpddr.2015.05.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Revised: 05/05/2015] [Accepted: 05/06/2015] [Indexed: 12/18/2022]
Abstract
In order to identify new compounds to treat Chagas disease during the acute phase with higher activity and lower toxicity than the reference drug benznidazole (Bz), two hydroxyphthalazine derivative compounds were prepared and their trypanocidal effects against Trypanosoma cruzi were evaluated by light microscopy through the determination of IC50 values. Cytotoxicity was determined by flow cytometry assays against Vero cells. In vivo assays were performed in BALB/c mice, in which the parasitemia levels were quantified by fresh blood examination; the assignment of a cure was determined by reactivation of blood parasitemia levels after immunosuppression. The mechanism of action was elucidated at metabolic and ultra-structural levels, by 1H NMR and TEM studies. Finally, as these compounds are potentially capable of causing oxidative damage in the parasites, the study was completed, by assessing their activity as potential iron superoxide dismutase (Fe-SOD) inhibitors. High-selectivity indices observed in vitro were the basis of promoting one of the tested compounds to in vivo assays. The tests on the murine model for the acute phase of Chagas disease showed better parasitemia inhibition values than those found for Bz. Compound 2 induced a remarkable decrease in the reactivation of parasitemia after immunosuppression. Compound 2 turned out to be a great inhibitor of Fe-SOD. The high antiparasitic activity and low toxicity together with the modest costs for the starting materials render this compound an appropriate molecule for the development of an affordable anti-Chagas agent. Low toxicity alternative treatment against Trypanosoma cruzi in murine model. The acute and chronic phases of Chagas disease. In vitro evaluation against epimastigote, amastigote and trypomastigote forms. Compound 2 selectively inhibits the parasite Fe-SOD enzyme. Compound 2 should be followed-up in future clinical experiments.
Collapse
|
14
|
Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model. Eur J Med Chem 2014; 89:683-90. [PMID: 25462275 DOI: 10.1016/j.ejmech.2014.11.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 10/29/2014] [Accepted: 11/01/2014] [Indexed: 12/22/2022]
Abstract
Chagas disease, caused by the protozoa parasite Trypanosoma cruzi, is an example of extended parasitaemia with unmet medical needs. Current treatments based on old-featured benznidazole (Bz) and nifurtimox are expensive and do not fulfil the criteria of effectiveness, and a lack of toxicity devoid to modern drugs. In this work, a group of abietic acid derivatives that are chemically stable and well characterised were introduced as candidates for the treatment of Chagas disease. In vitro and in vivo assays were performed in order to test the effectiveness of these compounds. Finally, those which showed the best activity underwent additional studies in order to elucidate the possible mechanism of action. In vitro results indicated that some compounds have low toxicity (i.e. >150 μM, against Vero cell) combined with high efficacy (i.e. <20 μM) against some forms of T. cruzi. Further in vivo studies on mice models confirmed the expectations of improvements in infected mice. In vivo tests on the acute phase gave parasitaemia inhibition values higher those of Bz, and a remarkable decrease in the reactivation of parasitaemia was found in the chronic phase after immunosuppression of the mice treated with one of the compounds. The morphological alterations found in treated parasites with our derivatives confirmed extensive damage; energetic metabolism disturbances were also registered by (1)H NMR. The demonstrated in vivo activity and low toxicity, together with the use of affordable starting products and the lack of synthetic complexity, put these abietic acid derivatives in a remarkable position toward the development of an anti-Chagasic agent.
Collapse
|
15
|
Olmo F, Rotger C, Ramírez-Macías I, Martínez L, Marín C, Carreras L, Urbanová K, Vega M, Chaves-Lemaur G, Sampedro A, Rosales MJ, Sánchez-Moreno M, Costa A. Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease. J Med Chem 2014; 57:987-99. [PMID: 24410674 DOI: 10.1021/jm4017015] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Access to basic drugs is a major issue in developing countries. Chagas disease caused by Trypanosoma cruzi is a paradigmatic example of a chronic disease without an effective treatment. Current treatments based on benznidazole and nifurtimox are expensive, ineffective, and toxic. N,N'-Squaramides are amide-type compounds that feature both hydrogen bond donor and acceptor groups and are capable of multiple interactions with complementary sites. When combined with amine and carboxylic groups, squaramide compounds have increased solubility and therefore make suitable therapeutic agents. In this work, we introduce a group of Lipinski's rule of five compliant squaramides as candidates for treating Chagas disease. The in vivo studies confirmed the positive expectations arising from the preliminary in vitro studies, revealing compound 17 to be the most effective for both acute and chronic phases. The activity, stability, low cost of starting materials, and straightforward synthesis make amino squaramides appropriate molecules for the development of an affordable anti-Chagasic agent.
Collapse
Affiliation(s)
- Francisco Olmo
- Departamento de Parasitología, Facultad de Ciencias, Universidad de Granada , E-18071 Granada, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Sánchez-Moreno M, Gómez-Contreras F, Navarro P, Marín C, Olmo F, Yunta MJR, Sanz AM, Rosales MJ, Cano C, Campayo L. Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection. J Med Chem 2012; 55:9900-13. [PMID: 23043291 DOI: 10.1021/jm3011004] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of new phthalazine derivatives 1-4 containing imidazole rings were prepared. The monoalkylamino substituted derivatives 2 and 4 were more active in vitro against T. cruzi and less toxic against Vero cells than both their disubstituted analogues and the reference drug benznidazole. Compounds 2 and 4 highly inhibited the antioxidant parasite enzyme Fe-SOD, and molecular modeling suggested that they interact with the H-bonding system of the iron atom moiety. In vivo tests on the acute phase of Chagas disease gave parasitemia inhibition values twice those of benznidazole, and a remarkable decrease in the reactivation of parasitemia was found in the chronic phase for immunodeficient mice. Glucose metabolism studies showed that compounds 1-4 did not affect the succinate pathway but originated important changes in the excretion of pyruvate metabolites. The morphological alterations found in epimastigotes treated with 1-4 confirmed extensive cytoplasm damage and a high mortality rate of parasites.
Collapse
Affiliation(s)
- Manuel Sánchez-Moreno
- Departamento de Parasitología, Facultad de Ciencias, Universidad de Granada, E-18071 Granada, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|